Latest in Gsk

Sort by

2 items

GSK to buy US cancer drug firm IDRx for up to $1.15bn

Massachusetts-based company is working on new treatments for gastrointestinal cancers. Business live – latest updates GSK has struck a deal worth up to $1.15bn (£950m) to acquire a ...
The Guardian - 1d
GSK nears $1bn deal for biotech developing drug for rare tumour

IDRx tests treatment for digestive system cancer that affects 4,000 to 6,000 people a year in US
Financial Times - 6d